The pharmacogenetics and pharmacogenomics of asthma therapy

DSpace/Manakin Repository

The pharmacogenetics and pharmacogenomics of asthma therapy

Citable link to this page


Title: The pharmacogenetics and pharmacogenomics of asthma therapy
Author: Tse, Sze Man; Tantisira, Kelan; Weiss, Scott Tillman

Note: Order does not necessarily reflect citation order of authors.

Citation: Tse, S M, K Tantisira, and S T Weiss. 2011. The pharmacogenetics and pharmacogenomics of asthma therapy. The Pharmacogenomics Journal 11, no. 6: 383–392. doi:10.1038/tpj.2011.46.
Full Text & Related Files:
Abstract: Despite the availability of several classes of asthma medications and their overall effectiveness, a significant portion of patients fail to respond to these therapeutic agents. Evidence suggests that genetic factors may partly mediate the heterogeneity in asthma treatment response. This review discusses important findings in asthma pharmacogenetics and pharmacogenomics studies conducted to date, examines limitations of these studies and finally, proposes future research directions in this field. The focus will be on the three major classes of asthma medications: β-adrenergic receptor agonists, inhaled corticosteroids and leukotriene modifiers. Although many studies are limited by small sample sizes and replication of the findings is needed, several candidate genes have been identified. High-throughput technologies is also allowing for large-scale genetic investigations. Thus, the future is promising for a personalized treatment of asthma, which will improve therapeutic outcomes, minimize side effects and lead to a more cost-effective care.
Published Version: doi:10.1038/tpj.2011.46
Other Sources:
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at
Citable link to this page:
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search